Stockreport

Arcutis Announces Enrollment of First Patient in Topical Roflumilast Cream Phase 3 Open Label Extension Study in Plaque Psoriasis

Arcutis Biotherapeutics, Inc. - Common stock  (ARQT) 
PDF Topical Roflumilast Cream (ARQ-151) Potential “Best in Class” Topical PDE4 inhibitorRoflumilast Cream Potentially Only Topical PDE4 inhibitor for PsoriasisOpen Label Ext [Read more]